isoxazoles has been researched along with bms 207940 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barrish, JC; Bird, E; Chen, P; Chong, S; Gu, Z; Hermsmeier, M; Humphreys, WG; Koplowitz, B; Leith, L; Liu, EC; Marino, A; Mathur, A; Moreland, S; Morrison, RA; Murugesan, N; Spergel, S; Trippodo, N; Waldron, T; Webb, ML; Young, M; Zhang, R | 1 |
1 other study(ies) available for isoxazoles and bms 207940
Article | Year |
---|---|
Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective
Topics: Administration, Oral; Animals; Blood Pressure; Caco-2 Cells; Carotid Arteries; CHO Cells; Cricetinae; Endothelin Receptor Antagonists; Humans; In Vitro Techniques; Isoxazoles; Macaca fascicularis; Male; Muscle Contraction; Oxazoles; Rabbits; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Structure-Activity Relationship; Sulfonamides | 2003 |